SG11202106470TA - Jak1 pathway inhibitors for the treatment of gastrointestinal disease - Google Patents
Jak1 pathway inhibitors for the treatment of gastrointestinal diseaseInfo
- Publication number
- SG11202106470TA SG11202106470TA SG11202106470TA SG11202106470TA SG11202106470TA SG 11202106470T A SG11202106470T A SG 11202106470TA SG 11202106470T A SG11202106470T A SG 11202106470TA SG 11202106470T A SG11202106470T A SG 11202106470TA SG 11202106470T A SG11202106470T A SG 11202106470TA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- gastrointestinal disease
- pathway inhibitors
- jak1 pathway
- jak1
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 208000010643 digestive system disease Diseases 0.000 title 1
- 208000018685 gastrointestinal system disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781877P | 2018-12-19 | 2018-12-19 | |
| US201962854801P | 2019-05-30 | 2019-05-30 | |
| US201962901377P | 2019-09-17 | 2019-09-17 | |
| PCT/US2019/067418 WO2020132210A1 (en) | 2018-12-19 | 2019-12-19 | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106470TA true SG11202106470TA (en) | 2021-07-29 |
Family
ID=69326646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106470TA SG11202106470TA (en) | 2018-12-19 | 2019-12-19 | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11596632B2 (enExample) |
| EP (1) | EP3897627A1 (enExample) |
| JP (1) | JP7624922B2 (enExample) |
| KR (1) | KR20210116487A (enExample) |
| CN (1) | CN113692278A (enExample) |
| AU (1) | AU2019403304B2 (enExample) |
| CA (1) | CA3123596A1 (enExample) |
| IL (1) | IL284034A (enExample) |
| MA (1) | MA54544A (enExample) |
| MX (1) | MX2021007260A (enExample) |
| PH (1) | PH12021551455A1 (enExample) |
| SG (1) | SG11202106470TA (enExample) |
| TW (1) | TWI884142B (enExample) |
| WO (1) | WO2020132210A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111566095B (zh) | 2017-11-03 | 2024-09-27 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法 |
| US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| US11372003B2 (en) | 2018-04-13 | 2022-06-28 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11021482B2 (en) | 2018-08-10 | 2021-06-01 | Adaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| KR20210116487A (ko) | 2018-12-19 | 2021-09-27 | 인사이트 코포레이션 | 위장 질환의 치료를 위한 jak1 경로 억제제 |
| IL285999B1 (en) | 2019-03-05 | 2025-09-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| WO2024102778A1 (en) * | 2022-11-08 | 2024-05-16 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of itk mediated conditions |
| WO2025144781A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| CN120699157B (zh) * | 2025-07-16 | 2025-12-16 | 安康市中心医院 | 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01013458A (es) | 1999-06-25 | 2002-07-30 | Genentech Inc | Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2. |
| ES2225624T3 (es) | 2000-06-28 | 2005-03-16 | Smithkline Beecham Plc | Procedimiento de molienda por via humeda. |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP2263691B1 (en) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| MX354212B (es) * | 2010-03-10 | 2018-02-19 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| BR112015009942A2 (pt) | 2012-11-01 | 2017-07-11 | Incyte Corp | derivados de tiofeno fundidos tricíclicos como inibidores de jak |
| TWI634121B (zh) | 2013-03-06 | 2018-09-01 | 英塞特控股公司 | 用於製備ｊａｋ抑制劑之方法及中間物 |
| WO2014186706A1 (en) | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
| MX394928B (es) | 2013-08-07 | 2025-03-24 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| HUE049775T2 (hu) * | 2015-11-24 | 2020-10-28 | Theravance Biopharma R&D Ip Llc | Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei |
| CN110072519A (zh) | 2016-12-14 | 2019-07-30 | 普罗根尼蒂公司 | 使用jak抑制剂治疗胃肠道疾病及装置 |
| WO2018111327A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of jak inhibitors at the site of gastrointestinal tract disease |
| KR20210116487A (ko) | 2018-12-19 | 2021-09-27 | 인사이트 코포레이션 | 위장 질환의 치료를 위한 jak1 경로 억제제 |
-
2019
- 2019-12-19 KR KR1020217022692A patent/KR20210116487A/ko active Pending
- 2019-12-19 JP JP2021535585A patent/JP7624922B2/ja active Active
- 2019-12-19 CA CA3123596A patent/CA3123596A1/en active Pending
- 2019-12-19 MA MA054544A patent/MA54544A/fr unknown
- 2019-12-19 US US16/720,465 patent/US11596632B2/en active Active
- 2019-12-19 SG SG11202106470TA patent/SG11202106470TA/en unknown
- 2019-12-19 CN CN201980090047.2A patent/CN113692278A/zh active Pending
- 2019-12-19 PH PH1/2021/551455A patent/PH12021551455A1/en unknown
- 2019-12-19 MX MX2021007260A patent/MX2021007260A/es unknown
- 2019-12-19 EP EP19842939.1A patent/EP3897627A1/en active Pending
- 2019-12-19 AU AU2019403304A patent/AU2019403304B2/en active Active
- 2019-12-19 TW TW108146771A patent/TWI884142B/zh active
- 2019-12-19 WO PCT/US2019/067418 patent/WO2020132210A1/en not_active Ceased
-
2021
- 2021-06-15 IL IL284034A patent/IL284034A/en unknown
-
2023
- 2023-01-31 US US18/103,662 patent/US12150943B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202038944A (zh) | 2020-11-01 |
| WO2020132210A1 (en) | 2020-06-25 |
| US20230172939A1 (en) | 2023-06-08 |
| US20200197399A1 (en) | 2020-06-25 |
| KR20210116487A (ko) | 2021-09-27 |
| EP3897627A1 (en) | 2021-10-27 |
| JP7624922B2 (ja) | 2025-01-31 |
| JP2022514089A (ja) | 2022-02-09 |
| US12150943B2 (en) | 2024-11-26 |
| TWI884142B (zh) | 2025-05-21 |
| AU2019403304A1 (en) | 2021-07-08 |
| AU2019403304B2 (en) | 2025-09-04 |
| PH12021551455A1 (en) | 2022-04-18 |
| US11596632B2 (en) | 2023-03-07 |
| MX2021007260A (es) | 2021-09-08 |
| MA54544A (fr) | 2021-10-27 |
| CN113692278A (zh) | 2021-11-23 |
| CA3123596A1 (en) | 2020-06-25 |
| IL284034A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284034A (en) | JAK1 pathway inhibitors for the treatment of gastrointestinal disease | |
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| IL276725A (en) | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | |
| IL276398B1 (en) | Combination therapy for mastocytosis | |
| IL275496A (en) | Glycolate oxidase inhibitors to treat the disease | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL287904B1 (en) | Combined treatment of arthritis | |
| IL267805B (en) | Compounds useful for the treatment of gastrointestinal disorders | |
| IL276482A (en) | Compounds for pain management | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL281782A (en) | Drug combination for cancer treatment | |
| HK40060694A (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| HK40049516A (en) | Kdm1a inhibitors for the treatment of disease | |
| GB201809835D0 (en) | Treatment of gastrointestinal disease | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| GB201901130D0 (en) | Formulation for the treatment of tendinopathies | |
| GB201811912D0 (en) | Treatment of disease | |
| GB201811911D0 (en) | Treatment of disease | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201810974D0 (en) | Treatment of disease |